[Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus].
Kuznik. B I BI; Isakova. N V NV; Kliuchereva. N N NN; Maleeva. N V NV; Pinelis. I S IS
Key Findings
- Vilon increased natural anticoagulants (antithrombin III, protein C) and boosted fibrinolysis, improving coagulation balance.
- Patients required less insulin to keep blood sugar stable after adding Vilon to their regimen.
- Abnormal immune cell counts (T‑helpers, NK cells) and IgA levels moved toward normal levels with Vilon.
Practical Outcomes
- For biohackers interested in diabetes management, Vilon appears to modestly improve blood clotting and reduce insulin requirements, which could be attractive for longevity and metabolic health goals. However, the study lacks detailed dosage, safety, and larger‑scale validation, so any self‑experiment should start with very low doses, close monitoring of coagulation markers, and consultation with a medical professional.
Summary
A small study gave the peptide Vilon to older people with type I diabetes and saw better blood clotting balance, a lower insulin need, and a more normal immune profile. The changes suggest Vilon might help manage diabetes‑related blood and immune issues, but the research is limited and doesn’t give clear dosing guidance.
Abstract
Improving the status of elderly patients with diabetes mellitus is an important issue of gerontology and geriatrics. This work was aimed at the study of the effect of thymomimetic Vilon on the immune status and coagulation hemostasis in elderly patients with type I diabetes mellitus. It was found that the administration of Vilon as an addition to the complex therapy for this cohort of patients resulted in optimization of coagulation hemostasis, which was manifested in the increased content of natural anticoagulants: antithrombin III and protein C, as well as in the stimulation of fibrinolysis. In most cases Vilon reduced the dose of insulin necessary for the stabilization of carbohydrate metabolism. The content of T-helpers, T-dependent and non-T-dependent NK cells was reduced, and the level of active T-lymphocytes, B-lymphocytes and IgA was normalized, which points out the stabilizing effect of Vilon on the immune system and hemostasis.
Study Information
pubmed
2007